Introduction: Adverse drug reactions (ADRs) represent a public health problem worldwide
that deserves attention due to the impact on mortality, morbidity, and healthcare costs. Drug …

Cardiovascular diseases (CVDs) are the leading cause of mortality globally. Wald and Law
proposed the idea of a “polypill”; a fixed dose combination therapy (FDC) in the form of a …

Background: Concomitant use of several drugs for a patient is often imposing increased risk
of drug–drug interactions. Drug–drug interactions are a major cause for concern in patients …

Background Incidence of drug–drug interactions (DDIs) increases with complexity of
treatment and comorbidities, as in heart failure (HF). This randomized, double-blind study …

Background: Polypharmacy is considered as one of the major risk factors in precipitation of
drug-drug interactions (DDIs). Patient population at high risk include the elderly and patients …

Objective: Cardiovascular disease (CVD) drugs have been frequently implicated in adverse
drug reaction (ADR)-related hospitalizations. Drug–drug interactions (DDIs) are common …

Background The treatment of heart failure patients is very complex and includes lifestyle
modification as well as different pharmacological therapies. Polypharmacy is very common …

Background Drug-related problems are associated with high mortality, complications,
prolonged hospital stay, compromised quality of life, and increased healthcare costs. This …

Drug–drug interactions (DDIs) and associated toxicity from cardiovascular drugs represents
a major problem for effective co-administration of cardiovascular therapeutics. A significant …

Purpose Although vitamin K antagonists (VKAs) are effective for long-term
thromboprophylaxis in atrial fibrillation (AF), their limitations have led to widespread …